Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome

[1] Clark H(2013)NCDs: a challenge to sustainable human development Lancet 381 510-511

[2] Roth GA(2017)Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 J Am Coll Cardiol 70 1-25

[3] Johnson C(2016)Heart disease and stroke statistics-2016 update: a report from the American Heart Association Circulation 133 e38-e360

[4] Abajobir A(2018)Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 20072017 Cardiovasc Diabetol 17 83-262

[5] Mozaffarian D(2019)Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors Curr Diab Rep 19 44-128

[6] Benjamin EJ(2011)Cardiovascular disease in recent onset diabetes mellitus J Cardiol 57 257-287

[7] Go AS(2006)Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease Am J Cardiol 98 121-1390

[8] Einarson TR(2007)The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease Pharmacol Rev 59 251-1906

[9] Acs A(2001)Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial Lancet 357 1385-259

[10] Ludwig C(2003)Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893-785

[1] Clark H(2013)NCDs: a challenge to sustainable human development Lancet 381 510-511

[2] Roth GA(2017)Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 J Am Coll Cardiol 70 1-25

[3] Johnson C(2016)Heart disease and stroke statistics-2016 update: a report from the American Heart Association Circulation 133 e38-e360

[4] Abajobir A(2018)Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 20072017 Cardiovasc Diabetol 17 83-262

[5] Mozaffarian D(2019)Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors Curr Diab Rep 19 44-128

[6] Benjamin EJ(2011)Cardiovascular disease in recent onset diabetes mellitus J Cardiol 57 257-287

[7] Go AS(2006)Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease Am J Cardiol 98 121-1390

[8] Einarson TR(2007)The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease Pharmacol Rev 59 251-1906

[9] Acs A(2001)Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial Lancet 357 1385-259

[10] Ludwig C(2003)Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893-785